Paying For Promises

Why do consumers spend freely on $200 face creams backed by no clinical evidence while abandoning $50 prescriptions proven in trials involving thousands of patients? Why does $70 billion flow annually to supplements that often don't contain what's on the label, while proven generic medications go unfilled because of cost?Paying for Promises is a guided tour through what author Richard Warburg calls the Promise Economy - the vast marketplace where everything from cancer drugs to collagen powders is ultimately selling you a promise, but where the evidence required to back those promises varies wildly.
Warburg, a molecular biologist, patent attorney, and biotech entrepreneur who has spent decades at the intersection of science, business, and regulation, unpacks the systems most consumers never think about. Through the conversations of two recurring characters - Alex, a savvy but susceptible young consumer, and Morgan, her industry-veteran friend - the book makes complex regulatory and economic territory not just accessible but genuinely engaging.
Part One reveals how the system works: the billion-dollar gauntlet of FDA drug approval, the 510(k) device pathway that lets medical devices reach market based on similarity to predecessors rather than new clinical proof, the insurance maze of pharmacy benefit managers and formulary decisions, and the emerging world of personalized medicine where a genetic test can mean the difference between a drug that saves your life and one that does nothing.
Part Two exposes the unregulated zones. The supplement industry operates under the 1994 DSHEA Act with almost no pre-market oversight - the FDA inspects roughly 5% of facilities annually. The beauty industry requires no proof whatsoever that its "revolutionary peptide technology" does anything at all. Sports supplements, celebrity vitamin brands, and ingestible collagen occupy a regulatory shadow where marketing fills the gap left by absent evidence.
Part Three ties it together: patent strategies that keep drug prices high, the GLP-1 gold rush with 157 obesity drugs in development, the uncomfortable economics of marginal innovation, and a practical framework for evaluating any health or wellness claim you encounter. The appendices provide the evidence: a Supplement Hall of Shame documenting products that failed independent testing, fraud case files, economic comparisons across the healthcare landscape, a BS Detection Toolkit, and complete chapter-by-chapter source notes.
This is not a book that tells you what to buy. It's a book that gives you the tools to evaluate every health and beauty promise you'll ever encounter - and to understand who profits when you can't tell the difference between real medicine and expensive hope.